NCT01040689 - Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

January 31, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Olodaterol (BI1744) Low

Low dose inhaled orally once daily from Respimat inhaler

DRUG

Placebo (for olodaterol BI1744)

Placebo (olodaterol low and high dose)delivered by Respimat

DRUG

Placebo (for Tiotropium)

Placebo (Tiotropium 18 mcg) delivered by HandiHaler

DRUG

Olodaterol (BI1744) High

High dose inhaled orally once daily from Respimat inhaler

DRUG

Tiotropium 18 mcg

18mcg inhaled once daily from Handihaler

Trial Locations (15)

1222.39.32003 Boehringer Ingelheim Investigational Site, Genk

1222.39.32001 Boehringer Ingelheim Investigational Site, Ghent

1222.39.32002 Boehringer Ingelheim Investigational Site, Hasselt

1222.39.45001 Boehringer Ingelheim Investigational Site, Hvidovre

1222.39.45003 Boehringer Ingelheim Investigational Site, Kolding

1222.39.45002 Boehringer Ingelheim Investigational Site, Odense C

1222.39.49391 Boehringer Ingelheim Investigational Site, Berlin

1222.39.49392 Boehringer Ingelheim Investigational Site, Hamburg

1222.39.49393 Boehringer Ingelheim Investigational Site, Mannheim

1222.39.36006 Boehringer Ingelheim Investigational Site, Deszk

1222.39.36004 Boehringer Ingelheim Investigational Site, Farkasgyepü

1222.39.36005 Boehringer Ingelheim Investigational Site, Pécs

1222.39.36003 Boehringer Ingelheim Investigational Site, Szarvas

1222.39.36001 Boehringer Ingelheim Investigational Site, Szeged

1222.39.36002 Boehringer Ingelheim Investigational Site, Törökbálint